DOCSLIB.ORG

A New Treatment for Seborrheic Dermatitis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A New Treatment for Seborrheic Dermatitis Pimecrolimus: A New Treatment for Seborrheic Dermatitis Charles E. Crutchfield III, MMB, MD Seborrheic dermatitis is a chronic recurrent involved in the inflammatory response. Specifically, inflammatory skin condition that mainly affects pimecrolimus inhibits calcineurin, a calcium- areas containing sebaceous glands. I present a dependent phosphatase enzyme. As a result, macrolac- case of a novel effective topical nonsteroidal tam immunomodulators also are known as calcineurin treatment (pimecrolimus 1.0% cream) for facial inhibitors. Calcineurin is essential in activating a seborrheic dermatitis. Pimecrolimus is a member nuclear transcription factor of activated T cells—a of a new class of nonsteroidal agents— factor that enhances production of many of the macrolactam immunomodulators. cytokines involved in the inflammatory response. Pimecrolimus seems to not produce the side effects eborrheic dermatitis is a chronic recurrent common with chronic use of topical steroids.7,8 inflammatory skin condition that affects the S nasolabial folds, ears, eyebrows, scalp (dan- Case Report druff), chest, umbilicus, and other areas containing A 33-year-old man presented with pink-to-red sebaceous glands.1 This condition also may have patches and plaques on the central area of the face hormonal influences—hence the appearance of (including the nasolabial folds) and overlying greasy seborrheic dermatitis on both the scalp in infants scales (Figure 1A). Ear, scalp, and chest involve- younger than 6 months (cradle cap) and on sebum- ment was minimal. The rash, which had been 1-3 1 rich areas in postadolescents. Seborrheic dermati- present intermittently for 1 /2 years, was progressing tis also has been associated with Pityrosporum in severity and frequency and was failing to respond yeasts, AIDS, and neurologic disease.4-6 The course to over-the-counter hydrocortisone 1% cream. The of the condition is usually intermittent, chronic, patient had no history of neurologic disease. Four and progressive. There is no known cause or cure months before presentation, he had had a general for seborrheic dermatitis, which affects 3% to 5% of physical examination, including a test for human the adult population.1 Standard treatment for facial immunodeficiency virus, and had been found to be seborrheic dermatitis relies heavily on topical in good health. glucocorticoids. Unfortunately, chronic use of A diagnosis of seborrheic dermatitis was made. topical steroids is associated with many side effects, The patient was instructed to apply approximately including atrophy, telangiectasia, glaucoma, 0.5 g of topical pimecrolimus 1.0% cream to adrenal suppression, and diminishing effectiveness.7 affected areas twice daily until he returned to the Pimecrolimus is a member of a new class of non- clinic for follow-up 14 days later. By follow-up, the steroidal agents—macrolactam immunomodulators. seborrheic dermatitis had cleared completely An ascomycin derivative, pimecrolimus has a (Figure 1B). The patient reported that clearing had molecular weight of 809 d. This agent was initially been complete on approximately day 8 but that he designated ASM 981 during development. Pime- had continued the regimen as instructed. At follow- crolimus, like the related macrolide agent up, he was instructed to start a preventive regimen tacrolimus, exerts its anti-inflammatory effects by (once-daily applications, weekends only) and to inhibiting production of many of the cytokines treat any breakthrough recurrences with 3 to 10 days of twice-daily applications. From private practice in Eagan, Minnesota, and the University Comment of Minnesota. Reprints: Charles E. Crutchfield III, MMB, MD, 1185 Town Center Dr, Seborrheic dermatitis is a frustrating, recurrent, Suite 101, Eagan, MN 55123 chronic inflammatory skin condition of unknown (e-mail: [email protected]). cause and cure. Mainstays of treatment have been VOLUME 70, OCTOBER 2002 207 Seborrheic Dermatitis Figure not available online Figure not available online A B Facial seborrheic dermatitis before (A) and after (B) 14 days of twice-daily application of topical pimecrolimus 1.0% cream. topical corticosteroid preparations, antifungal 4. Wikler JR, Nieboer C, Willemze R. Quantitative skin creams, and antidandruff/antifungal shampoos.1,9,10 cultures of Pityrosporum yeasts in patients seropositive for Unfortunately, these treatments can become inef- the human immunodeficiency virus with and without fective, and certain risks are associated with long- seborrheic dermatitis: seborrheic dermatitis in patients term use of steroids on the face. Reported here is a with acquired immunodeficiency syndrome. J Am Acad case of facial seborrheic dermatitis successfully Dermatol. 1992;27:37-39. treated with pimecrolimus 1.0% cream. What is 5. Mathes BM, Douglass MC. Seborrheic dermatitis in unclear is whether the molecular size of pime- patients with acquired immunodeficiency syndrome. J Am crolimus makes this agent less than maximally effec- Acad Dermatol. 1985;13:947-951. tive (by virtue of forming a barrier to penetration) in 6. Binder RL, Jonelis FJ. Seborrheic dermatitis in neuroleptic- treating inflammatory skin disorders with epithelial induced parkinsonism. Arch Dermatol. 1983;119:473-475. disruption—as occurs with tacrolimus. Neverthe- 7. Bornhovd E, Burgdorf WH, Wollenberg A. Macrolactam less, because of the significant effectiveness and immunomodulators for topical treatment of inflam- minimal side-effect profile of pimecrolimus in treat- matory skin diseases. J Am Acad Dermatol. ing atopic dermatitis and seborrheic dermatitis, this 2001;45:736-743. agent may be used to treat a variety of inflammatory 8. Nghiem P, Pearson G, Langly RG. Tacrolimus and skin conditions. Pimecrolimus represents a promis- pimecrolimus: from clever prokaryotes to inhibiting cal- ing alternative to topical glucocorticoids, especially cineurin and treating atopic dermatitis. J Am Acad when it is desirable to minimize or avoid their use. Dermatol. 2002;46:228-241. 9. Green CA, Farr PM, Shuster S. Treatment of seborrhoeic REFERENCES dermatitis with ketoconazole, II: response of seborrhoeic 1. Ackerman AB, Kerl H, Sanchez J, et al, eds. A Clinical dermatitis of the face, scalp and trunk to topical ketocona- Atlas of 101 Common Skin Diseases With Histopathologic zole. Br J Dermatol. 1987;116:217-221. Correlation. New York, NY: Ardor Scribendi Ltd; 2000. 10. Peter RU, Richarz-Barthauer U. Successful treatment and 2. Webster G. Seborrheic dermatitis. Int J Dermatol. prophylaxis of scalp seborrhoeic dermatitis and dandruff 1991;30:843-844. with 2% ketoconazole shampoo: results of a multicentre, 3. Mimouni K, Mukamel M, Zaharia A, et al. Prognosis of double-blind, placebo-controlled trial. Br J Dermatol. infantile seborrheic dermatitis. J Pediatr. 1995;127:744-746. 1995;132:441-445. 208 CUTIS®.
Load more

Recommended publications
  • Where Does Psoriasis Fit
    Dr Shan Edwards Dermatologist Dermatology Clinic, Christchurch 11:00 - 11:55 WS #86: Differential Diagnosis Based on Classic Location - Where Does Psoriasis Fit In? 12:05 - 13:00 WS #97: Differential Diagnosis Based on Classic Location - Where Does Psoriasis Fit In? (Repeated) Differential diagnosis based on classic location Where does psoriasis fit in? Dr Shan Edwards , dermatologist Christchurch 2016 2 Conflict statement . This talk sponsored by LEO Pharma Pty Ltd . I have no other association financial or otherwise with LEO Pharma Pty Ltd 3 Acknowedgement I wish to thank and acknowledge and thank A/Prof Amanda Oakley for providing a lot of the material and allowing me to use it in this talk I would also like to acknowledge Dermnet NZ as a source for most of my clinical slides 4 How do you diagnose red scaly skin ? Take a history (90% diagnosis made on history) . When did scaly rash first appear? . What do you think caused it? . What treatments used and their effects? . Personal history of skin problems ? . Family history of similar disorders? . Occupation, hobbies, other life events? . Symptoms: itch? Other eg fever, weightloss unwell Other medical problems?(co-morbidities) . Current medicines : how long, any new ? 7 When did scaly rash first appear? . Infancy: seborrhoeic dermatitis/eczema . Toddler: atopic dermatitis/eczema . Pre-schooler/primary school: tinea capitis/corporis . Primary school: head lice . Teenage/adult: seborrhoeic dermatitis/eczema, psoriasis . Adult/elderly: drug rash, lymphoma, other less common skin conditions(PRP,Lupus) . All age groups:scabies 8 Dear Shan Re: Miss EM age 7yrs I am completely puzzled by EM’s rash and particularly so since there now appear to be other areas of her body being affected by it.
    [Show full text]
  • Autoimmune Associations of Alopecia Areata in Pediatric Population - a Study in Tertiary Care Centre
    IP Indian Journal of Clinical and Experimental Dermatology 2020;6(1):41–44 Content available at: iponlinejournal.com IP Indian Journal of Clinical and Experimental Dermatology Journal homepage: www.innovativepublication.com Original Research Article Autoimmune associations of alopecia areata in pediatric population - A study in tertiary care centre Sagar Nawani1, Teki Satyasri1,*, G. Narasimharao Netha1, G Rammohan1, Bhumesh Kumar1 1Dept. of Dermatology, Venereology & Leprosy, Gandhi Medical College, Secunderabad, Telangana, India ARTICLEINFO ABSTRACT Article history: Alopecia areata (AA) is second most common disease leading to non scarring alopecia . It occurs in Received 21-01-2020 many patterns and can occur on any hair bearing site of the body. Many factors like family history, Accepted 24-02-2020 autoimmune conditions and environment play a major role in its etio-pathogenesis. Histopathology shows Available online 29-04-2020 bulbar lymphocytes surrounding either terminal hair or vellus hair resembling ”swarm of bees” appearance depending on chronicity of alopecia areata. Alopecia areata in children is frequently seen. Pediatric AA has been associated with atopy, thyroid abnormalities and a positive family history. We have done a study to Keywords: find out if there is any association between alopecia areata and other auto immune diseases in children. This Alopecia areata study is an observational study conducted in 100 children with AA to determine any associated autoimmune Auto immunity conditions in them. SALT score helps to assess severity of alopecia areata. Severity of alopecia areata was Pediatric population assessed by SALT score-1. S1- less than 25% of hairloss, 2. S2- 25-49% of hairloss, 3. 3.S3- 50-74% of hairloss.
    [Show full text]
  • Lupus and the Skin a Patient’S Guide to Skin Involvement in Lupus
    Lupus and the Skin A Patient’s Guide to Skin Involvement in Lupus © LUPUSUK 2015 LUPUS and the Skin LUPUS UK acknowledges with gratitude the assistance of Sue Brown, Consultant Nurse in Rheumatology (Connective Tissue Diseases), Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath and Dr Chris Lovell, Consultant Dermatologist, Royal United Hospital and Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath in the provision of clinical information towards the production of this booklet. ACKNOWLEDGEMENT The authors would like to thank Professor Peter Maddison, Consultant Rheumatologist and Dr Andrew Macfarlane, Consultant Dermatologist at Ysbyty Gwynedd, Bangor, Wales, who wrote the first edition of this booklet and have kindly agreed to its revision. LUPUS UK is the national charity caring for those with systemic lupus erythematosus (SLE) and discoid lupus erythematosus (DLE), supporting people as they develop the symptoms prior to diagnosis and those already diagnosed. You can help by taking up membership For more information contact: LUPUS UK, St James House, Eastern Road, Romford, Essex RM1 3NH Tel: 01708 731251 www.lupusuk.org.uk Reg. charity nos 1051610, SC039682 © LUPUS UK 2012 All rights reserved. No part of this book may be reproduced in any form without written permission from LUPUS UK. Index Section Page No 1 Introduction 1 2 Types of rashes 2 3 Mechanism of photosensitivity 5 4 Treatment of the skin in lupus 7 5 Sun protection 10 6 Quality of life 11 7 Fatigue 12 8 Self help 12 9 Research 14 10 Further reading 14 1. Introduction Many people with lupus may have skin problems, and a rash may be the first sign of the condition.
    [Show full text]
  • The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis Rana Herro1, Ricardo Da S
    ORIGINAL ARTICLE The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis Rana Herro1, Ricardo Da S. Antunes1, Amelia R. Aguilera1, Koji Tamada2 and Michael Croft1 Several inflammatory diseases including scleroderma and atopic dermatitis display dermal thickening, epidermal hypertrophy, or excessive accumulation of collagen. Factors that might promote these features are of interest for clinical therapy. We previously reported that LIGHT, a TNF superfamily molecule, mediated collagen deposition in the lungs in response to allergen. We therefore tested whether LIGHT might similarly promote collagen accumulation and features of skin fibrosis. Strikingly, injection of recombinant soluble LIGHT into naive mice, either subcutaneously or systemically, promoted collagen deposition in the skin and dermal and epidermal thickening. This replicated the activity of bleomycin, an antibiotic that has been previously used in models of scleroderma in mice. Moreover skin fibrosis induced by bleomycin was dependent on endogenous LIGHT activity. The action of LIGHT in vivo was mediated via both of its receptors, HVEM and LTβR, and was dependent on the innate cytokine TSLP and TGF-β. Furthermore, we found that HVEM and LTβR were expressed on human epidermal keratinocytes and that LIGHT could directly promote TSLP expression in these cells. We reveal an unappreciated activity of LIGHT on keratinocytes and suggest that LIGHT may be an important mediator of skin inflammation and fibrosis in diseases such as scleroderma
    [Show full text]
  • Scalp Eczema Factsheet the Scalp Is an Area of the Body That Can Be Affected by Several Types of Eczema
    12 Scalp eczema factsheet The scalp is an area of the body that can be affected by several types of eczema. The scalp may be dry, itchy and scaly in a chronic phase and inflamed (red), weepy and painful in an acute (eczema flare) phase. Aside from eczema, there are a number of reasons why the scalp can become dry and itchy (e.g. psoriasis, fungal infection, ringworm, head lice etc.), so it is wise to get a firm diagnosis if there is uncertainty. Types of eczema • Hair clips and headgear – especially those containing that affect the scalp rubber or nickel. Seborrhoeic eczema (dermatitis) is one of the most See the NES booklet on Contact Dermatitis for more common types of eczema seen on the scalp and hairline. details. It can affect babies (cradle cap), children and adults. The Irritant contact dermatitis is a type of eczema that skin appears red and scaly and there is often dandruff as occurs when the skin’s surface is irritated by a substance well, which can vary in severity. There may also be a rash that causes the skin to become dry, red and itchy. on other parts of the face, such as around the eyebrows, For example, shampoos, mousses, hair gels, hair spray, eyelids and sides of the nose. Seborrhoeic eczema can perm solution and fragrance can all cause irritant contact become infected. See the NES factsheets on Adult dermatitis. See the NES booklet on Contact Dermatitis for Seborrhoeic Dermatitis and Infantile Seborrhoeic more details. Dermatitis and Cradle Cap for more details.
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • Eczema of Infancy and Childhood
    International Journal of Medicine Research International Journal of Medicine Research ISSN: 2455-7404; Impact Factor: RJIF 5.42 Received: 23-02-2020; Accepted: 21-03-2020; Published: 11-04-2020 www.medicinesjournal.com Volume 5; Issue 2; 2020; Page No. 21-23 Eczema of infancy and childhood Dr. Magida Kathm1, Dr. Baraa W Taha2, Dr. Nassema Lazim3 1, 2, 3 Centeral Teaching Hospital of Peadiatrics, Baghdad, Iraq Abstract Background: Eczema of infancy and childhood is one of the commom dermatological diseases in Iraqi patients for this reason this study was arranged. Objective: To assessment of an epidemiological study aimed at characterization of different clinical aspects of eczema in children and in infants in Iraqi population. Patient and Methods: A total number of tow hundred and fifty patients was seen and studied in the department of dermatology / Medical City Baghdad, FROM December 2013 to April 2014. They were 131 males and 119 female. Their ages ranged from 2 weeks to 12 years, mean age 4.43 years with mean age of onset was 3.65 years. A detailed history was taken from each patient with emphasis on the following relivant points: age, age of onset, sex, family history of atopy, personal history of atopy, history of food allergy, any associated diseases and any seasonal variations. All patients were fully examined regarding the type, morphology and distribution of the lesions in each type of eczema including: Atopic dermatitis, discoid eczema, pityriasis Alba and seborrhoeic dermatitis. The type of feeding whether breast, bottle or mixed feeding was assessed in all types of eczema.
    [Show full text]
  • Health Economics and Dermatology
    Extracts from the Lectures of the 32nd Nordic Congress of Dermato-Venereology, Tampere, Finland Hyperpigmentation is a common symptom but will not pro- vide much valuable information to help diagnosing the skin condition. Almost all skin diseases in dark skin can give hyper- pigmentation at some point, especially if they have a chronic or protracted course. A non-specific hyperchromia can darken the elementary lesions of the underlying dermatosis, which could mislead the physician when examining the patient. Hyperpigmentation is the main cause of consultation of dark- skinned patients but the list of causes of hyperpigmentation is countless, thus topography and additional signs should help the physician. Three conditions are of particular exception, namely acne, lichen planus and prurigo lesions in HIV patients. Hypopigmentation on the other hand is an important sign for diagnosis and hypopigmentation also severely impairs the quality of life of the patients. Causes of permanent achromia Fig. 2. Prurigo nodularis in include mainly vitiligo, post-traumatic achromia, idiopathic an HIV patients. Typical Fig. 3. Heterogenous depigmentation hypomelanosis, chronic lupus of the discoid type, and burns. annular pigmented itchy induced by skin bleaching agents. lesions with central depig- Causes of mottled hypopigmentation include vitiligo, systemic mentation. scleroderma and lichenification. Lastly, frequent causes of hypopigmentation include eczema, seborrhoeic dermatitis, pityriasis versicolor, vitiligo minor, injection or local treat- systemic complications. As users tend to hide the use of such ment of corticosteroids, achromic hamartoma, lichen striatus agents to the physician it is important to treat any underlying or verruca plana. Rare causes of hypopigmentation include skin dermatoses, disrupt bleaching agents, avoid any judge- mycosis fungoides, sarcoidosis and leprosy.
    [Show full text]
  • Updates in Pediatric Dermatology
    Peds Derm Updates ELIZABETH ( LISA) SWANSON , M D ADVANCED DERMATOLOGY COLORADO ROCKY MOUNTAIN HOSPITAL FOR CHILDREN [email protected] Disclosures Speaker Sanofi Regeneron Amgen Almirall Pfizer Advisory Board Janssen Powerpoints are the peacocks of the business world; all show, no meat. — Dwight Schrute, The Office What’s New In Atopic Dermatitis? Impact of Atopic Dermatitis Eczema causes stress, sleeplessness, discomfort and worry for the entire family Treating one patient with eczema is an example of “trickle down” healthcare Patients with eczema have increased risk of: ADHD Anxiety and Depression Suicidal Ideation Parental depression Osteoporosis and osteopenia (due to steroids, decreased exercise, and chronic inflammation) Impact of Atopic Dermatitis Sleep disturbances are a really big deal Parents of kids with atopic dermatitis lose an average of 1-1.5 hours of sleep a night Even when they sleep, kids with atopic dermatitis don’t get good sleep Don’t enter REM as much or as long Growth hormone is secreted in REM (JAAD Feb 2018) Atopic Dermatitis and Food Allergies Growing evidence that food allergies might actually be caused by atopic dermatitis Impaired barrier allows food proteins to abnormally enter the body and stimulate allergy Avoiding foods can be harmful Proper nutrition is important Avoidance now linked to increased risk for allergy and anaphylaxis Refer severe eczema patients to Allergist before 4-6 mos of age to talk about food introduction Pathogenesis of Atopic Dermatitis Skin barrier
    [Show full text]
  • Effectiveness of Medium-Dose Ultraviolet A1 Phototherapy in Localized Scleroderma
    Pharmacology and therapeutics Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma Ozlem Su1, MD, Nahide Onsun1, MD, Hulya Kapran Onay2, MD, Yeliz Erdemoglu1, MD, Dilek Biyik Ozkaya1, MD, Filiz Cebeci1, MD, and Adnan Somay3, MD 1Department of Dermatology, Abstract Bezmialem Vakif University, Faculty of Background Recently, ultraviolet (UV) A1 phototherapy has been suggested as an effec- 2 Medicine, Neoson Imaging Center, tive treatment for localized scleroderma (LS); however, the optimal dose of UVA1 still has Radiology, and 3Department of not been determined. Pathology, Vakif Gureba Teaching and 2 Research Hospital, Istanbul, Turkey Objective We aimed to evaluate the therapeutic effectiveness of medium-dose (30 J/cm ) UVA1 phototherapy and to show that 13 MHz ultrasound is a valuable tool for assessing Correspondence the results of UVA1 phototherapy in LS. Ozlem Su, MD Methods Thirty-five patients with LS were treated with medium-dose (30 J/cm2) UVA1. Sıgırtmac Sok. No. 21 B blok d. 7 In total, 30–45 treatments and 900–1350 J/cm2 cumulative UVA1 doses were evaluated by Osmaniye Bakirkoy clinical scoring in all patients. In 14 patients, skin thickness was also determined by Istanbul 13 MHz ultrasound examination. Turkey Results In all patients, medium-dose UVA1 therapy softened sclerotic plaques, and E-mail: [email protected] marked clinical improvement was observed in 29 of 35 (82. 85%) patients. Ultrasound mea- surements showed that skin thickness was significantly reduced. No side effects were Conflicts of interest: None. observed during or after treatment. Conclusion Medium-dose UVA1 phototherapy is a highly effective, safe, and well-tolerated therapeutic modality for treatment of all types of LS.
    [Show full text]
  • Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, Or Psoriasis: a Review of Clinical and Cost- Effectiveness
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost- Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: September 25, 2017 Report Length: 19 Pages Authors: Raywat Deonandan, Melissa Severn Cite As: Pimecrolimus for the treatment of adults with atopic dermatitis, seborrheic dermatitis, or psoriasis: a review of clinical and cost- effectiveness. Ottawa: CADTH; 2017 Sep. (CADTH rapid response report: summary with critical appraisal). Acknowledgments: ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
    [Show full text]
  • Decreased Adhesion Molecules Expression on Granuloma Forming
    THE EGYPTIAN JOURNAL OF IMMUNOLOGY Vol. 22 (1), 2015 Page: 29-40 Level of IL-16 and Reticulated Platelets Percentage during the Clinical Course of Immune Thrombocytopenic Purpura in Children 1Reem R. Abd El-Glil, 2Effat H. Assar Departments of 1Microbiology & Immunology and 2Pediatric, Faculty of Medicine, Benha University, Benha, Egypt. Immune thrombocytopenic purpura (ITP) is an immune-mediated acquired disease with transient or persistent decrease of thrombocytes number in the blood. Cytokines play important roles in the immune regulation and are known to be deregulated in autoimmune diseases. This study aimed to investigate serum IL-16 levels in relation to reticulated platelets in children with ITP and platelet count. Twenty six children with ITP (11 with newly diagnosed ITP, 9 with persistent ITP and 6 with chronic ITP) and 12 age-matched healthy children controls were studied. Serum level of IL-16 and reticulated platelets count were assessed by Enzyme Linked Immunosorbent Assay (ELISA) and flow cytometry respectively. Serum IL-16 levels were significantly higher in patients as compared to controls (P<0.001).Within patients, the levels were higher in newly diagnosed compared to persistent and chronic ITP (P<0.01) and (P<0.001) respectively. IL-16 levels were also significantly higher in persistent ITP compared to chronic ITP (P<0.001). Reticulated platelets were also elevated in patients compared to controls and the increase was significant in newly diagnosed group (P<0.05). Negative correlation was found between IL-16 level and reticulated platelets and platelets counts (r=-0.284, P=0.028, r=0.274 P=0.25) respectively.
    [Show full text]